Engineered immune cells take aim at a common pancreatic cancer mutation
NCT ID NCT07649928
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests an experimental drug called ES502 in people with advanced pancreatic cancer that has a specific genetic change (RAS G12V) and who have run out of standard treatments. ES502 is a lab-made protein designed to guide the body's immune T-cells to attack cancer cells carrying that mutation. The study's main goals are to check the drug's safety and find the best dose, while also watching for any signs that tumors shrink or stop growing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ES502 injection (a bispecific T-cell receptor fusion protein targeting RAS G12V)
What this could lead to
If successful, this could point toward a new treatment option for people with advanced pancreatic cancer who have the RAS G12V mutation and no other options.
What could go wrong
This is a very early, small study (24 people) focused on safety. The treatment may not shrink tumors or could cause serious side effects. Success in this phase does not guarantee broader benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, 200025, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••